Back to News
Market Impact: 0.18
Matricelf Gets FDA Feedback Backing First-in-Human Trial For NewRal Spinal Cord Injury Program
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Matricelf (MTLF) said the U.S. FDA provided written feedback supporting key elements of its proposed first-in-human clinical trial of NewRal. The update is a constructive regulatory step for the trial plan, but no efficacy, timing, or trial start date was specified.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Mistral bags $24 billion valuation as Samsung leads funding for Europe's AI champion
- Cholesterol drug setback casts doubt over multibillion-dollar race
- Bathla collapse, data center boom, Ingenia Communities
- Nvidia supplier Wistron's shares drop after it announces $1.5 billion global stock sale
- Global markets keep shrugging off shocks. Here's what could break that streak, according to HSBC
- Dell Stock Jumped 15% Last Week. Here's Why This Top AI Stock Is Still a Buy